Restoring metabolic balance AND WEIGHT CONTROL

Harnessing precision-targeted drug formulations for the treatment and prevention of metabolic disorders such as obesity and related diseases

Our Approach

Metabolic disorders such as obesity or type 2 diabetes have emerged as a health and economic problem of global proportions, largely due to excessive consumption of calorie-rich highly refined food, sedentary lifestyles, and disruptions to circadian rhythms in modern work and living environments.

Aphaia is committed to offering patients therapeutic options that provide long-term benefits with minimal or no side effects by restoring the body’s natural physiology.

LEARN MORE

APH-012

LEAD DRUG CANDIDATE

We believe that our drug lead candidate, a proprietary oral glucose formulation, has the potential to revolutionize the treatment of metabolic disorders like obesity, type 2 diabetes, and associated diseases by addressing the underlying disease mechanism. It uniquely activates nutrient-sensing cells in the distal small intestine, restoring the endogenous release of the full spectrum of enteral hormones that control appetite, hunger, satiety, glucose metabolism, and other homeostatic functions.

LEARN MORE

Programs

PHASE 2 TRIALS IN OBESITY AND PREDIABETES

Aphaia’s lead drug candidate is being evaluated in two Phase 2 trials. The first proof-of-concept study in individuals with obesity evaluates its ability to change weight and other key parameters, hallmarking multiple metabolic diseases associated with obesity in a placebo-controlled design. The second trial is evaluating the drug’s ability to help prevent type 2 diabetes.

LEARN MORE

News

Aphaia Pharma Publishes Phase 1 and 2 Clinical Data of Oral Formulation

09/23/2025

Aphaia Pharma Publishes Phase 1 and 2 Clinical Data of Oral Formulation in Patients with Obesity and Prediabetes

Aphaia’s lead formulation orchestrates a comprehensive hormonal response from nutrient-sensing cells with potential to modify the course of obesity and associated metabolic diseases.
It is currently under evaluation in a Phase 2 trial in individuals with obesity, following positive Phase 2 trial data in patients with prediabetes

Aphaia Pharma Initiates Second Phase 2 Trial

09/09/2025

Aphaia Pharma Initiates Second Phase 2 Trial of Oral Candidate in Obesity

Second Phase 2 trial builds on encouraging initial results from a prior Phase 2 study
Aphaia’s formulation activates gastrointestinal nutrient-sensing signaling pathways to modify the course of obesity and associated metabolic diseases

Aphaia Pharma to Participate at SXSW 2025

02/20/2025

Aphaia Pharma to Participate in Panel Discussion at SXSW 2025

ZUG, Switzerland, SAN JUAN, Puerto Rico and TORONTO, February 20, 2025 – Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of obesity and associated metabolic diseases, today announced that Steffen-Sebastian Bolz, MD, Ph.D., Chief Scientific Officer of Aphaia Pharma, will participate in a panel discussion at SXSW, taking place March 7-15, 2025, in Austin, Texas.

All news